The Protocol Specific Research Support (PSRS) of the UNM Cancer Center functions to support early phase investigator-initiated pilot studies that lack sponsored support. Early phase unsupported investigator-initiated clinical trials are proposed at the Clinical Working Group level, and reviewed by the Protocol Review Committee (at UNM termed the Medical and Scientific Review Committee) for scientific merit. Should they be approved at this level, and lack support, they are submitted to the Clinical Research Committee for consideration of institutional support. This PSRS review is chaired by C. Verschraegen, MD, the member of the Clinical Research Committee responsible for organizing PSRS evaluations. Should the unsupported protocols be deemed worthy of support, they are then submitted to an appropriate IRB, and if approved, implemented by the Clinical Protocol, Data Management, and Informatics Shared Resource with protocol specific financial support. The PSRS research nurse is M. Pruess, and the data manager is M. Allred. In FY 2008/9 there were 19 investigator-initiated Phase l-lll interventional clinical trials that required UNM Cancer Center support. These trials accrued 222 total patients in the FY 2008/9. In FY 2008/9 there were 11 investigator-initiated phase I or l/ll interventional clinical trials that were supported by the UNM Cancer Center. These trials accrued 52 total patients. These trials were innovative pilot projects that were designed to lead to larger externally supported later phase clinical trials. This significant UNM Cancer Center support of early phase investigator-initiated clinical trials demonstrates an active Protocol Specific Research Support program.

Public Health Relevance

Developing effective new cancer therapies is important since the survival of many patients with cancer is still poor. Not all new therapies are financially supported, especially those developed individually by UNM Cancer Center clinical investigators. The Protocol Specific Research support mechanism provides support for new cancer treatments that have no other financial support. This increases the number of new treatments that can be tested here.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of New Mexico Health Sciences Center
United States
Zip Code
Steffen, Laurie E; Du, Ruofei; Gammon, Amanda et al. (2017) Genetic Testing in a Population-Based Sample of Breast and Ovarian Cancer Survivors from the REACH Randomized Trial: Cost Barriers and Moderators of Counseling Mode. Cancer Epidemiol Biomarkers Prev 26:1772-1780
Cleyrat, C├ędric; Girard, Romain; Choi, Eun H et al. (2017) Gene editing rescue of a novel MPL mutant associated with congenital amegakaryocytic thrombocytopenia. Blood Adv 1:1815-1826
Oruganti, S R; Torres, D J; Krebsbach, S et al. (2017) CARMA1 is a novel regulator of T-ALL disease and leukemic cell migration to the CNS. Leukemia 31:255-258
Belinsky, Steven A; Leng, Shuguang; Wu, Guodong et al. (2017) Gene Methylation Biomarkers in Sputum and Plasma as Predictors for Lung Cancer Recurrence. Cancer Prev Res (Phila) 10:635-640
Hill, Deirdre A; Barry, Marc; Wiggins, Charles et al. (2017) Estrogen receptor quantitative measures and breast cancer survival. Breast Cancer Res Treat 166:855-864
Meyer, Matthias R; Rosemann, Thomas; Barton, Matthias et al. (2017) GPER Mediates Functional Endothelial Aging in Renal Arteries. Pharmacology 100:188-193
Flores, Kristina G; Steffen, Laurie E; McLouth, Christopher J et al. (2017) Factors Associated with Interest in Gene-Panel Testing and Risk Communication Preferences in Women from BRCA1/2 Negative Families. J Genet Couns 26:480-490
Wang, Jing; Samuels, David C; Zhao, Shilin et al. (2017) Current Research on Non-Coding Ribonucleic Acid (RNA). Genes (Basel) 8:
Leng, Shuguang; Wu, Guodong; Klinge, Donna M et al. (2017) Gene methylation biomarkers in sputum as a classifier for lung cancer risk. Oncotarget 8:63978-63985
Kimura, Tomonori; Jia, Jingyue; Kumar, Suresh et al. (2017) Dedicated SNAREs and specialized TRIM cargo receptors mediate secretory autophagy. EMBO J 36:42-60

Showing the most recent 10 out of 272 publications